Neal Walker - Mar 1, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Director
Signature: /s/ Mark Ballantyne, Attorney-in-fact
Stock symbol: ACRS
Transactions as of: Mar 1, 2023
Transactions value $: -$740,658
Form type: 4
Date filed: 3/3/2023, 07:37 PM
Previous filing: Feb 3, 2023
Next filing: Jul 5, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+96.2K	+8.18%		1.27M	Mar 1, 2023	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+18.3K	+1.44%		1.29M	Mar 1, 2023	Direct	F1
transaction	ACRS	Common Stock	Options Exercise		+24K	+1.86%		1.31M	Mar 1, 2023	Direct	F1
transaction	ACRS	Common Stock	Sale	-$359K	-29K	-2.21%	$12.37	1.29M	Mar 2, 2023	Direct	F2, F3
transaction	ACRS	Common Stock	Options Exercise		+18.3K	+1.42%		1.3M	Mar 2, 2023	Direct	F1
transaction	ACRS	Common Stock	Sale	-$382K	-30.2K	-2.32%	$12.63	1.27M	Mar 3, 2023	Direct	F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-96.2K	-100%	$0.00^*	0	Mar 1, 2023	Common Stock	96.2K		Direct	F1, F6
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-18.3K	-33.33%	$0.00	36.6K	Mar 1, 2023	Common Stock	18.3K		Direct	F1, F7
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-24K	-25%	$0.00	72K	Mar 1, 2023	Common Stock	24K		Direct	F1, F8
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-18.3K	-50%	$0.00	18.3K	Mar 2, 2023	Common Stock	18.3K		Direct	F1, F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 pursuant to preexisting sell-to-cover elections.
F3	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $11.88 to $12.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4	Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on March 1, 2023 and March 2, 2023 pursuant to preexisting sell-to-cover elections.
F5	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $12.39 to $12.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6	The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
F7	The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
F8	The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 1, 2023, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.
F9	The shares underlying these restricted stock units were originally scheduled to vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date. Pursuant to the Letter Agreement dated November 22, 2022 the shares underlying these restricted stock units will cease vesting on December 31, 2023.